Impact of HIV and Its Treatment on Reverse Cholesterol Transport
NCT ID: NCT00168233
Last Updated: 2012-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
44 participants
OBSERVATIONAL
2005-06-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HIV Reverse Cholesterol Transport Study
NCT01670968
IL-7 Receptor Polymorphisms and Immune Recovery With HAART
NCT00168207
Subclinical Atherosclerosis in HIV-infected Patients
NCT00455793
Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers
NCT00253682
HealthMap: an Interactive Health Plan Randomised Trial to Prevent Cardiovascular Disease in People With HIV
NCT02178930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No antiretroviral therapy for 12 months
No interventions assigned to this group
2
Initiating ARV therapy with an NNRTI based regimen
No interventions assigned to this group
3
Initiating ARV therapy with a PI based regimen
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months)
* HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen)
* HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen
Exclusion Criteria
* Body Mass Index greater than 27.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Health and Medical Research Council, Australia
OTHER
The Alfred
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jennifer Hoy
Professor Jennifer Hoy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dmitri Sviridov, Dr
Role: STUDY_DIRECTOR
Baker Heart Research Institute, Commercial Road, Melbourne
Jennifer Hoy, A/Prof
Role: PRINCIPAL_INVESTIGATOR
Alfred Hospital, Melbourne, Vic 3004
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alfred Hospital and Baker Heart Research Institute
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
54/05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.